Sanofi Sues Mylan Over Blocking its EpiPen Competitor, Auvi-Q

Generic Line
A A
In a lawsuit filed Monday, Sanofi says Mylan’s anticompetitive business practices blocked its EpiPen competitor, the Auvi-Q, from gaining a foothold in the epinephrine auto-injector market, resulting in hundreds of millions in lost sales.

To View This Article:

Login

Subscribe To Generic Line